RNA binding protein with multiple splicing-like pseudogeneGenealiases: []
Q-omics provides the consensus-scored RBPMSLP profile across patient tissues and cancer cell-line models. RBPMSLP expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBPMSLP is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, RBPMSLP RNA expression shows 6,644 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BLCA, and STAD as cancer lineages where RBPMSLP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBPMSLP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBPMSLP survival associations across molecular data types. RBPMSLP RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBPMSLP RNA expression–survival associations across cancer types. High RBPMSLP expression shows unfavorable associations in ACC, UVM, TGCT, THYM and DLBC, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBPMSLP RNA expression.
This table summarizes RBPMSLP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RBPMSLP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBPMSLP shows lower tumor expression in KIRP and ESCA and higher tumor expression in BLCA, STAD and PRAD. The BLCA box plot shows higher RBPMSLP RNA expression in tumor versus normal tissue (log2 FC = +0.160, t-test p = .007).
This table shows molecular features associated with RBPMSLP in patient tissues and cancer cell lines. In patient samples, RBPMSLP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
